Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4,979	5,085	4,570	10,369	10,504	6,795
Short-Term Investments	1,324	1,523	1,546	849.2	274.5	729.9
Cash & Short-Term Investments	6,303	6,608	6,116	11,218	10,779	7,525
Cash Growth	0.26%	8.05%	-45.48%	4.08%	43.24%	13.00%
Accounts Receivable	2,311	2,053	1,609	1,563	1,442	1,137
Receivables	2,311	2,053	1,609	1,563	1,442	1,137
Inventory	2,245	1,687	1,205	738.8	460.6	353.1
Prepaid Expenses	732.1	736.2	459.2	537.6	431.6	442.1
Restricted Cash	9.3	-	-	-	-	5.1
Other Current Assets	85.3	117.1	206.5	86.1	121.9	98.6
Total Current Assets	11,686	11,201	9,596	14,144	13,235	9,561
Property, Plant & Equipment	3,329	3,083	2,585	1,453	1,456	1,424
Long-Term Investments	3,606	5,794	5,173	2,498	112.2	-
Goodwill	2,423	1,088	1,088	1,088	1,088	1,002
Other Intangible Assets	8,518	424.2	825.9	839.9	603.6	400
Long-Term Deferred Tax Assets	1,953	2,898	2,331	1,812	1,247	934.5
Long-Term Deferred Charges	-	66.6	62.6	58.9	40.2	-
Other Long-Term Assets	1,221	1,089	871.9	836.4	369.4	110.8
Total Assets	32,736	25,643	22,533	22,730	18,151	13,433

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	472.6	461.7	413	364.9	303.9	195
Accrued Expenses	3,235	2,782	2,584	2,556	2,003	1,467
Short-Term Debt	999.6	-	-	-	-	-
Current Portion of Leases	-	82.8	92.3	83.7	89.4	80.2
Current Income Taxes Payable	-	103.1	161.1	99.5	123.3	211.3
Current Unearned Revenue	124.4	171.8	206.8	170.3	159.6	171.7
Other Current Liabilities	168.6	259.7	107.4	273.2	62.5	16.5
Total Current Liabilities	5,000	3,861	3,565	3,547	2,742	2,142
Long-Term Debt	3,497	-	-	-	-	-
Long-Term Leases	1,982	1,953	1,657	724.7	810.3	887.2
Other Long-Term Liabilities	1,350	1,163	901.8	877.7	685.8	303.3
Total Liabilities	11,829	6,977	6,124	5,150	4,238	3,333

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	2.5	2.5	2.6	2.6	2.6	2.5
Additional Paid-In Capital	4,503	5,119	6,672	7,450	7,387	6,881
Retained Earnings	16,345	13,560	9,607	10,142	6,523	3,201
Comprehensive Income & Other	57.2	-15.9	127.8	-14.3	0.8	15.9
Total Common Equity	20,907	18,666	16,410	17,580	13,913	10,100
Shareholders' Equity	20,907	18,666	16,410	17,580	13,913	10,100
Total Liabilities & Equity	32,736	25,643	22,533	22,730	18,151	13,433

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	6,478	2,036	1,750	808.4	899.7	967.4
Net Cash (Debt)	3,343	10,284	9,474	12,908	9,991	6,558
Net Cash Growth	-67.15%	8.55%	-26.60%	29.19%	52.36%	14.71%
Net Cash Per Share	13.07	39.86	36.74	49.55	38.56	25.23
Filing Date Shares Outstanding	253.54	254.03	256.79	258.31	257.09	254.58
Total Common Shares Outstanding	253.52	253.99	256.94	257.7	257.01	254.48
Working Capital	6,686	7,340	6,032	10,597	10,493	7,419
Book Value Per Share	82.47	73.49	63.87	68.22	54.13	39.69
Tangible Book Value	9,966	17,154	14,496	15,653	12,221	8,698
Tangible Book Value Per Share	39.31	67.54	56.42	60.74	47.55	34.18
Land	-	33.1	33.1	33.1	33.1	33.1
Buildings	-	483.8	461.2	928.6	903.1	892.5
Machinery	-	1,198	1,061	911.9	788.6	701
Leasehold Improvements	-	1,009	737.6	474.6	410.9	363.5

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 8, 2026

Data Sources Report a data error